Report Detail
Global Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2019
- RnM3192047 |
- 26 March, 2019 |
- Global |
- 97 Pages |
- QYResearch |
- Pharma & Healthcare
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
The global Myelodysplastic Syndrome (MDS) Treatment market is valued at 2210 million US$ in 2018 is expected to reach 5760 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2019-2025.
This report focuses on Myelodysplastic Syndrome (MDS) Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myelodysplastic Syndrome (MDS) Treatment market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Segment by Application
Refractory cytopenia with unilineage dysplasia
Refractory anemia with ringed sideroblasts
Others
Table of Contents
Executive Summary
1 Myelodysplastic Syndrome (MDS) Treatment Market Overview
- 1.1 Product Overview and Scope of Myelodysplastic Syndrome (MDS) Treatment
- 1.2 Myelodysplastic Syndrome (MDS) Treatment Segment by Type
- 1.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Azacitidine
- 1.2.3 Lenalidomide
- 1.2.4 Decitabine
- 1.2.5 Deferasirox
- 1.3 Myelodysplastic Syndrome (MDS) Treatment Segment by Application
- 1.3.1 Myelodysplastic Syndrome (MDS) Treatment Consumption Comparison by Application (2014-2025)
- 1.3.2 Refractory cytopenia with unilineage dysplasia
- 1.3.3 Refractory anemia with ringed sideroblasts
- 1.3.4 Others
- 1.4 Global Myelodysplastic Syndrome (MDS) Treatment Market by Region
- 1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Myelodysplastic Syndrome (MDS) Treatment Market Size
- 1.5.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue (2014-2025)
- 1.5.2 Global Myelodysplastic Syndrome (MDS) Treatment Production (2014-2025)
2 Global Myelodysplastic Syndrome (MDS) Treatment Market Competition by Manufacturers
- 2.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Myelodysplastic Syndrome (MDS) Treatment Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Myelodysplastic Syndrome (MDS) Treatment Production Sites, Area Served, Product Types
- 2.5 Myelodysplastic Syndrome (MDS) Treatment Market Competitive Situation and Trends
- 2.5.1 Myelodysplastic Syndrome (MDS) Treatment Market Concentration Rate
- 2.5.2 Myelodysplastic Syndrome (MDS) Treatment Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Myelodysplastic Syndrome (MDS) Treatment Production Market Share by Regions
- 3.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Market Share by Regions
- 3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Regions (2014-2019)
- 3.3 Global Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Myelodysplastic Syndrome (MDS) Treatment Production
- 3.4.1 North America Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate (2014-2019)
- 3.4.2 North America Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Myelodysplastic Syndrome (MDS) Treatment Production
- 3.5.1 Europe Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate (2014-2019)
- 3.5.2 Europe Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Myelodysplastic Syndrome (MDS) Treatment Production (2014-2019)
- 3.6.1 China Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate (2014-2019)
- 3.6.2 China Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Myelodysplastic Syndrome (MDS) Treatment Production (2014-2019)
- 3.7.1 Japan Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate (2014-2019)
- 3.7.2 Japan Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Myelodysplastic Syndrome (MDS) Treatment Consumption by Regions
- 4.1 Global Myelodysplastic Syndrome (MDS) Treatment Consumption by Regions
- 4.2 North America Myelodysplastic Syndrome (MDS) Treatment Consumption (2014-2019)
- 4.3 Europe Myelodysplastic Syndrome (MDS) Treatment Consumption (2014-2019)
- 4.4 China Myelodysplastic Syndrome (MDS) Treatment Consumption (2014-2019)
- 4.5 Japan Myelodysplastic Syndrome (MDS) Treatment Consumption (2014-2019)
5 Global Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price Trend by Type
- 5.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Market Share by Type (2014-2019)
- 5.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type (2014-2019)
- 5.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Type (2014-2019)
- 5.4 Global Myelodysplastic Syndrome (MDS) Treatment Production Growth by Type (2014-2019)
6 Global Myelodysplastic Syndrome (MDS) Treatment Market Analysis by Applications
- 6.1 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Market Share by Application (2014-2019)
- 6.2 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Myelodysplastic Syndrome (MDS) Treatment Business
- 7.1 Novartis AG
- 7.1.1 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.1.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Celgene Corporation
- 7.2.1 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Otsuka Pharmaceutical Co., Ltd
- 7.3.1 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.3.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Sandoz Inc
- 7.4.1 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.4.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Dr Reddys Laboratories Limited
- 7.5.1 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.5.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 Pharmascience Inc
- 7.6.1 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.6.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Accord Healthcare Ltd
- 7.7.1 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.7.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 Mylan N.V.
- 7.8.1 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production Sites and Area Served
- 7.8.2 Myelodysplastic Syndrome (MDS) Treatment Product Introduction, Application and Specification
- 7.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
8 Myelodysplastic Syndrome (MDS) Treatment Manufacturing Cost Analysis
- 8.1 Myelodysplastic Syndrome (MDS) Treatment Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Treatment
- 8.4 Myelodysplastic Syndrome (MDS) Treatment Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Myelodysplastic Syndrome (MDS) Treatment Distributors List
- 9.3 Myelodysplastic Syndrome (MDS) Treatment Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Myelodysplastic Syndrome (MDS) Treatment Market Forecast
- 11.1 Global Myelodysplastic Syndrome (MDS) Treatment Production, Revenue Forecast
- 11.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Myelodysplastic Syndrome (MDS) Treatment Price and Trend Forecast (2019-2025)
- 11.2 Global Myelodysplastic Syndrome (MDS) Treatment Production Forecast by Regions (2019-2025)
- 11.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Production, Revenue Forecast (2019-2025)
- 11.2.3 China Myelodysplastic Syndrome (MDS) Treatment Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Myelodysplastic Syndrome (MDS) Treatment Production, Revenue Forecast (2019-2025)
- 11.3 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Consumption Forecast (2019-2025)
- 11.3.2 Europe Myelodysplastic Syndrome (MDS) Treatment Consumption Forecast (2019-2025)
- 11.3.3 China Myelodysplastic Syndrome (MDS) Treatment Consumption Forecast (2019-2025)
- 11.3.4 Japan Myelodysplastic Syndrome (MDS) Treatment Consumption Forecast (2019-2025)
- 11.4 Global Myelodysplastic Syndrome (MDS) Treatment Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Myelodysplastic Syndrome (MDS) Treatment Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Myelodysplastic Syndrome (MDS) Treatment . Industry analysis & Market Report on Myelodysplastic Syndrome (MDS) Treatment is a syndicated market report, published as Global Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2019. It is complete Research Study and Industry Analysis of Myelodysplastic Syndrome (MDS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
